New NHS-Galleri study results show that the trial did not meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses. Secondary findings were more encouraging, although they should be interpreted cautiously. For i...
RGA Vice President and Actuary Taylor Pickett breaks down the research that went into the new Digital Underwriting Evidence (DUE) Playbook and how your business can benefit from it.
Read MoreRGA produces a number of specialized publications featuring expert opinion and analysis. Explore our public collection or contact us for whitepapers, webinars, and other resources.
Explore the industry's premier medical underwriting publication.
Explore the ReFlections SeriesInvestigate product development trends and developments from around the world.
Explore the Product Trends Series
